Hitting the Ground Running in 2014
Week in Review: Hitting the Ground Running in 2014
01.10.14 | By Kaelan Hollon
This year promises to be a busy, productive one for PhRMA and our member companies, and we started the week off right by focusing on several key industry issues, including rare diseases, STEM education, and medical advances.
In conjunction with the FDA, we’re kick starting the year by focusing on the important issue of combatting rare diseases. Duchenne Muscular Dystrophy is one of many rare diseases with limited treatment options, and in a guest-post, Holly Peay, Vice President of Education and Outreach for Parent Project Muscular Dystrophy, and Timothy Franson, Principal at FaegreBD Consulting, explained the challenges facing rare disease communities. Specifically referencing the development process for new treatments, they noted that with the help of patient organizations, gathering new information could drastically change health outcomes for patients suffering from rare diseases in the coming years.
The currently robust pipeline to combat rare and other devastating diseases would not be possible without the highly skilled science, technology, education and mathematics (STEM) workforce. Involved in every stage of the R&D process, STEM workers help to produce new treatments for our most challenging and costly diseases. To raise awareness of this important issue, we are partnering with U.S. News and World Report to host the STEM Saves Lives Event on January 22. The event will discuss the importance of STEM to the U.S. economy and address how the biopharmaceutical industry is looking to employ creative and sustainable approaches to improving STEM education. You can RSVP for the event here.
We also responded to an Xconomy article by Luke Timmerman this week that claimed the pharmaceutical industry is not doing enough to deliver “big health advances.” In a three-part series of blog posts, we explained the various ways the industry is working exceptionally hard for patients around the world. From implementing a hands-on approach to deliver vaccines to patients suffering from some of the world’s most debilitating diseases to utilizing PhRMA’s Scientific Leadership Advisory Council to further strengthen the R&D system, the pharmaceutical industry, often in conjunction with the FDA, continues to make significant progress in improving human health and well-being – something that certainly will not change in 2014.
Our events, posts and forums allow us to connect with the many different faces of the biopharmaceutical industry, and we will be expanding on these interactions in 2014. We’ll continue to post questions and engage in meaningful dialogue through our ‘Conversations’ forum and various events, and we encourage you to share your thoughts with us. In the first Conversations question of the year, our President and CEO John Castellani asked experts how we can harness mobile technologies to manage chronic diseases and improve patient health. Read what experts had to say, and join us in keeping the dialogue going on Facebook and Twitter.
Thanks for helping us make 2014 a year to remember.